Author

Jing Y. Wang

Institution: Tesaro (United States)

Observed institution: Tesaro (United States)

OpenAlex ID: A5006987969

TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.

2018 · Panagiotis A. Konstantinopoulos, Steven E. Waggoner, et al. · Journal of Clinical Oncology · 143

Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis.

2019 · Mansoor Raza Mirza, Bin Feng, et al. · Journal of Clinical Oncology · 5

Works count: 2

Citation count: 148

H-index: 2

I10-index: 1